IP Library › Granted Patent US 12,324,844
Granted Patent B2
US 12,324,844 · App. 17/126,340 · Granted Jun 10, 2025

MRI contrast agent including T1 contrast material coated on surface of nanoparticle support

Inventors: Jin Woo Cheon (Seoul, KR); Tae Hyun Shin (Yongin-si, KR)
Assignee: INVENTERA PHARMACEUTICALS INC.
A61K49/1878A61K49/08A61K49/126A61K49/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,324,844
App. No.
17/126,340
Granted
Jun 10, 2025
Kind
B2
Abstract

A magnetic resonance imaging (MRI) T1 contrast agent composition including T1 contrast material coated on the surface of a nanoparticle support and an imaging method using the MRI T1 contrast agent. The MRI T1 contrast agent composition has excellent T1 spin magnetic relaxation effects by modifying the paramagnetic T1 contrast material on the nanoparticle support having a certain diameter such that the paramagnetic T1 contrast material has a certain thickness or less, and thereby remarkably increasing the surface-to-volume ratio of the T1 contrast material. The MRI T1 contrast agent provides more precise and clear T1 positive contrast images, and is thus useful for highly reliable image diagnosis.

Claims (17)

1. A magnetic resonance imaging (MRI) method using an iron-based T1 contrast agent for obtaining T1-weighted images in MRI scan, comprising

(a) introducing the iron-based T1 contrast agent with a T1 relaxivity coefficient (r 1 ) value ranging from approximately 1 mM −1 s −1 to 5 mM −1 s −1 at 1.5 Tesla on an MRI scanner, into a body fluid of a subject, said iron-based T1 contrast agent producing a bright or positive contrast effect compared to water,

wherein the MRI iron-based T1 contrast agent consists of

(i) a non-magnetic nanoparticle support comprising SiO 2 , a polysaccharide, or a protein wherein a surface of the nanoparticle support comprises surface functional groups, and

(ii) an iron oxide coating layer having iron oxide bound by coordination bond to the surface functional groups,

wherein a ratio of thickness of the iron oxide coating layer to a diameter of the non-magnetic nanoparticle support is to 1:25 to 1:6; the diameter of the non-magnetic nanoparticle support is 2 to 40 nm; and the thickness of the iron oxide coating layer is 0.1 to 1 nm,

wherein the iron-based T1 contrast agent shortens T1 relaxation time (spin-lattice relaxation time) to induce a positive contrast on T1-weighted images without inducing a negative contrast associated with a T2 contrast agent; and

(b) obtaining T1-weighted images in MRI scan of body parts of the subject.

2. The MRI method of claim 1 , further comprising

(c) using the T1-weighted MRI images obtained from the step (b) as imaging information for medical diagnosis.

3. The MRI method of claim 1 , wherein the body parts of the subject are vessels.

4. The MRI method of claim 1 , wherein the polysaccharide is a dextran.

5. The MRI method of claim 1 , wherein the ratio of the thickness of the iron chelate oxide coating layer to the diameter of the non-magnetic nanoparticle support is 1:25 to 1:10.

6. The MRI method of claim 1 , wherein the ratio of the thickness of the iron oxide coating layer to the diameter of the non-magnetic nanoparticle support is 1:25.

7. The MRI method of claim 2 , wherein the imaging information is the presence or absence of bleeding in a lesion of the body parts of the subject.

8. The MRI method of claim 7 , wherein the body parts of the subject are vessels.

9. The MRI method of claim 1 , wherein the ratio of the thickness of the iron oxide coating layer to the diameter of the non-magnetic nanoparticle support is 1:10.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2023
From: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
To: INVENTERA PHARMACEUTICALS INC.
Reel/Frame 062755/0874 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2023
From: CHEON, JIN WOO; SHIN, TAE HYUN
To: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
Reel/Frame 062817/0986 →
Priority Claims (1)
KR 10-2013-0001002 · Jan 4, 2013 · national
Continuity (2)
Continuation 14759288
Related Publication 20210113717A1 · Apr 22, 2021
References Cited (47)
US 9040637B2 · Axelsson et al. · 2015 [cited by applicant]
US 20050265922A1 · Nie et al. · 2005 [cited by applicant]
US 20090011064A1 · Margel · 2009 [cited by applicant]
US 20090110644A1 · Margel et al. · 2009 [cited by applicant]
US 20110014296A1 · Chen et al. · 2011 [cited by applicant]
US 20110200534A1 · Cheon · 2011 [cited by examiner]
US 20140350193A1 · Axelsson et al. · 2014 [cited by applicant]
US 20160000942A1 · Cheon et al. · 2016 [cited by applicant]
US 20180361000A1 · Weissleder · 2018 [cited by applicant]
US 20190083660A1 · Cheon et al. · 2019 [cited by applicant]
CN 112089851 · 2020 [cited by applicant]
CN 112807449 · 2021 [cited by applicant]
EP 2942064 · 2015 [cited by applicant]
JP 2014534277 · 2014 [cited by applicant]
KR 1020150115760 · 2005 [cited by applicant]
KR 1020070058358 · 2007 [cited by applicant]
KR 1020080071463 · 2008 [cited by applicant]
KR 1020090033953 · 2009 [cited by applicant]
KR 1020100023778 · 2010 [cited by applicant]
KR 1020110050213 · 2011 [cited by applicant]
WO WO9962079 · 1999 [cited by applicant]
WO WO2010048268 · 2010 [cited by applicant]
WO WO2012020911 · 2012 [cited by applicant]
WO WO2014107055 · 2014 [cited by applicant]
Office Action from Chinese Application No. 202011048294.7, dated May 9, 2022, 13 pages (with machine translation). [cited by applicant]
Alric, C, et al., “Gadolinium Chelate Coated Gold Nanoparticles As Contrast Agents for Both X-ray Computed Tomography and Magnetic Resonance Imaging”, JAGS, pp. 5908-5915 (Year 2008). [cited by applicant]
Bridot, J., et al.; “Hybrid Gadolinium Oxide Nanoparticles: Multimodal Contrast Agents for in Vivo Imaging”, J. Am. Chem. Soc. 2007, 129, pp. 5076-5084. [cited by applicant]
Extended European Search Report from corresponding European Patent Application No. 17753543 2, dated Oct. 7, 2019, 10 pages. [cited by applicant]
Gole, A., et al.; “Iron Oxide Coated Gold Nanorods: Synthesis, Characterization, and Magnetic Manipulation”, Langmuir 2008, 24, pp. 6232-6237. [cited by applicant]
H.P Erickson et al., “Size and Shape of Protein Molecules at the Nanometer Level Determined by Sedimentation, Gel Filtration, and Electron Microscopy,” Biol. Proceed. Online, 2009, 11:32-51. [cited by applicant]
Hyeon et al., “Development of a contrast agent resonance imaging using nanoparticles,” Angew. Chem. Int. Ed., 2007, 46:5397-5. [cited by applicant]
International Preliminary Report on Patentability in Appln. No. PCT/KR2014/000062, dated Jul. 7, 2015, 10 pages. [cited by applicant]
International Preliminary Report on Patentability in Appln. No. PCT/KR2017/001852, dated Aug. 21, 2018, 11 pages. [cited by applicant]
International Search Report (ISR) from corresponding PCT Application No. PCT/KR2017/001852, dated Jun. 13, 2017 and its English translation, 10 pages. [cited by applicant]
International Search Report and Written Opinion in Appln. No. PCT/KR2014/000062, mailed Apr. 30, 2014, 9 pages. [cited by applicant]
Lee, J. H., et al.; “Artificially engineered magnetic nanoparticles for Ultra-sensitive molecular imaging”, Nature Medicine. vol. 13, No. 1, Jan. 2007, pp. 95-99. [cited by applicant]
Na, H. B., et al.; “Development of a T1 Contrast Agent for Magnetic Resonance Imaging Using MnO Nanoparticles”, Angew. Chem. Int. Ed. 2007, 46, pp. 5397-5401. [cited by applicant]
Office Action from corresponding Japanese Patent Application No. 2018-543635, dated Aug. 26, 2019, 8 pages. [cited by applicant]
Riviere et al., “Hybrod gadolimium oxide nanoparticles: multimodal contrast agents for vivo imaging,” J. Am. Chem. Soc., 2007, 129:5076-5084. [cited by applicant]
Ryu et al., “Synthesis and Electrochemical Characterization of Silica-Manganese Oxide with a Core-shell Structure and Various Oxidation States,” Bulletin of the Korean Chemical Society, 2011, vol. 32, No. 8, pp. 2683-26… [cited by applicant]
Shevchenko, E. V., et al.; “Gold/Iron Oxide Core/Hollow-Shell Nanoparticles”, Adv. Mater. 2008, 20, pp. 4323-4329. [cited by applicant]
Yang, H., et al.; “Targeted dual-contrast T1- and T2 weighted magnetic resonance imaging of tumors using multifunctional gadolinium-labeled superparamagnetic iron oxide nanoparticles”, Biomaterials 32 (2011) 4584-4593. [cited by applicant]
Ren et al., “Assembly Behavior of Iron Oxide-Capped Janus Particles in a Magnetic Field”, Langmuir, 2012, 28: 1149-1156. [cited by applicant]
Lee et al., “Super-paramagnetic iron oxide nanoparticles for use in extrapulmonary tuberculosis diagnosis,” Clinical Microbiology and Infection, Jun. 1, 2012, 18(6):E149-E157. [cited by applicant]
Sirlin et al., “Gadolinium-DTPA-dextran: A macromolecular MR blood pool contrast agent1,” Academic radiology, Dec. 1, 2004, 11(12):1361-1369. [cited by applicant]
Ersoy et al., “Biochemical Safety Profiles of Gadolinium-Based Extracellular Contrast Agents and Nephrogenic Systemic Fibrosis,” Journal of Magnetic Resonance Imaging, 2007, pp. 1-16. [cited by applicant]
Sauzedde et al., “Hydrophilic magnetic polymer latexes. 1. Adsorption of magnetic iron oxide nanoparticles onto various cationic latexes,” Colloid and Polymer Science, 1999, 277:846-855. [cited by applicant]